Journal article
A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer
Abstract
BackgroundPatients with ovarian cancer whose disease relapses or progresses within 6 months after frontline platinum- and taxane-containing therapy have a poor prognosis and limited treatment options. In this phase II study, the activity and safety profiles of patupilone, a novel microtubule-targeting agent, were assessed in patients with platinum-resistant or -refractory ovarian, primary fallopian tube, or primary peritoneal cancer.Patients …
Authors
Smit WM; Šufliarsky J; Werner TL; Dizon DS; Wagnerová M; Hirte HW; Spirtos NM; Oza A; Dirix L; El-Hashimy M
Journal
Clinical Ovarian and Other Gynecologic Cancer, Vol. 5, No. 2, pp. 53–59
Publisher
Elsevier
Publication Date
12 2012
DOI
10.1016/j.cogc.2012.06.001
ISSN
2212-9553